175 related articles for article (PubMed ID: 29884479)
1. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases.
Zhang G; Li B; Yin X; Gao S; Shen S; Wang H; Shi X; Liu W; Zheng K; Jing W; Zhang Y; He T; Li G; Hu X; Guo S; Jin G
Int J Surg; 2022 Aug; 104():106786. PubMed ID: 35868619
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
Kawaida H; Fujii H
Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
[No Abstract] [Full Text] [Related]
5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
7. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
8. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
[TBL] [Abstract][Full Text] [Related]
10. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
12. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
14. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
15. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
17. Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection.
Han SH; Heo JS; Choi SH; Choi DW; Han IW; Han S; You YH
Int J Surg; 2017 Apr; 40():68-72. PubMed ID: 28232032
[TBL] [Abstract][Full Text] [Related]
18. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
19. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
20. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
